Status:
UNKNOWN
Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
Lead Sponsor:
Poitiers University Hospital
Conditions:
Waldenstrom's Macroglobulinaemia Refractory
Eligibility:
All Genders
18+ years
Brief Summary
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute...
Eligibility Criteria
Inclusion
- Waldenstrom's macroglobulinemia
- Treatment with Venetoclax
- Non opposition
Exclusion
- none
Key Trial Info
Start Date :
December 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06200220
Start Date
December 28 2023
End Date
December 1 2025
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Poitiers
Poitiers, France, 86000